
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
AI Summary
- About


Waters Corporation (WAT)



- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)


(see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
02/20/2025: WAT (1-star) is a SELL. SELL since 4 days. Profits (-4.46%). Updated daily EoD!
Analysis of Past Performance
Type Stock | Historic Profit -9.25% | Avg. Invested days 42 | Today’s Advisory SELL |
Upturn Star Rating ![]() ![]() | Upturn Advisory Performance ![]() | Stock Returns Performance ![]() |
![]() ![]() | ![]() ![]() |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 22.26B USD | Price to earnings Ratio 35.03 | 1Y Target Price 398.96 |
Price to earnings Ratio 35.03 | 1Y Target Price 398.96 | ||
Volume (30-day avg) 471820 | Beta 1.01 | 52 Weeks Range 279.24 - 423.56 | Updated Date 02/21/2025 |
52 Weeks Range 279.24 - 423.56 | Updated Date 02/21/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 10.7 |
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-02-04 | When Before Market | Estimate 4.06 | Actual 4.1 |
Profitability
Profit Margin 21.56% | Operating Margin (TTM) 34.11% |
Management Effectiveness
Return on Assets (TTM) 11.83% | Return on Equity (TTM) 42.82% |
Valuation
Trailing PE 35.03 | Forward PE 29.41 | Enterprise Value 23912173820 | Price to Sales(TTM) 7.52 |
Enterprise Value 23912173820 | Price to Sales(TTM) 7.52 | ||
Enterprise Value to Revenue 8.08 | Enterprise Value to EBITDA 23.47 | Shares Outstanding 59376200 | Shares Floating 59267822 |
Shares Outstanding 59376200 | Shares Floating 59267822 | ||
Percent Insiders 0.29 | Percent Institutions 96.96 |
AI Summary
Waters Corporation: A Comprehensive Overview
Company Profile:
History and Background:
Founded in 1958, Waters Corporation is a global leader in analytical instruments and consumables for laboratory and research applications. Originally known for its chromatography systems, the company has expanded into mass spectrometry, thermal analysis, and other areas. Waters serves customers in various industries, including pharmaceuticals, environmental testing, food safety, and academia.
Core Business Areas:
- Chromatography: Instruments and consumables for separating and analyzing complex mixtures.
- Mass Spectrometry: Instruments and consumables for identifying and quantifying molecules.
- Informatics: Software and data management solutions for scientific research.
- Other: Thermal analysis, sample preparation, and laboratory equipment.
Leadership:
The company is led by Udit Batra, President, and Chief Executive Officer, and Michael Harrington, Chief Financial Officer. It operates under a Board of Directors, guided by ethical and transparent corporate governance principles.
Top Products & Market Share:
- ACQUITY UPLC Systems: Waters holds a dominant market share in ultra-performance liquid chromatography (UPLC), offering unmatched speed and resolution for complex analysis.
- Xevo Series Mass Spectrometers: These high-performance mass spectrometers deliver sensitive and accurate detection for various applications.
- Empower Chromatography Data Software: Empower is a comprehensive software platform for managing chromatography data, enabling efficient analysis and reporting.
Market share estimates vary depending on the specific product and market segment. However, Waters remains a major player in chromatography and mass spectrometry, with leading positions in many key segments.
Comparison against competitors:
Waters competes with players like Thermo Fisher Scientific, Agilent Technologies, and Danaher in the analytical instrumentation market. While competition is intense, Waters maintains a competitive edge through its innovative technology, strong brand recognition, and comprehensive product portfolio.
Total Addressable Market:
The global market for analytical instruments and consumables is estimated to be worth over $50 billion. Waters operates in a significant portion of this market, focusing on segments with high growth potential.
Financial Performance:
Recent Financial Statements:
- Revenue: $2.7 billion (2022)
- Net Income: $493 million (2022)
- Profit Margin: 18.2% (2022)
- EPS: $4.29 (2022)
Year-over-Year Comparison:
Waters has shown consistent revenue and earnings growth over the past years. Strong demand for its core products and strategic acquisitions have contributed to its financial performance.
Cash Flow & Balance Sheet:
The company maintains a healthy cash flow and a strong balance sheet, with minimal debt and ample liquidity.
Dividends & Shareholder Returns:
Dividend History:
Waters has a long history of paying dividends, with a current annual dividend yield of around 0.8%. The company has consistently increased its dividend payout in recent years.
Shareholder Returns:
Over the past year, Waters' stock has outperformed the S&P 500 index, delivering strong returns to shareholders.
Growth Trajectory:
Historical Growth:
Waters has shown consistent revenue and earnings growth over the past five to ten years, fueled by product innovation, strategic acquisitions, and expanding markets.
Future Growth Projections:
Analysts project continued growth for Waters in the coming years, driven by increasing demand in its core markets, new product launches, and emerging applications.
Market Dynamics:
The analytical instruments market is driven by several key factors, including:
- Increasing demand for accurate and reliable analytical data: Across various industries, the need for accurate and reliable analytical data continues to rise.
- Technological advancements: The development of new analytical techniques and instrumentation drives market growth.
- Growing focus on quality control and safety: Regulations and standards requiring stringent quality control and safety measures contribute to market expansion.
Market Position:
Waters holds a strong market position, well-positioned to capitalize on growth opportunities in its core markets and leverage its technological expertise to explore new applications.
Competitors:
- Thermo Fisher Scientific (TMO)
- Agilent Technologies (A)
- Danaher (DHR)
- PerkinElmer (PKI)
- Shimadzu Corporation (TYO: 7701)
Competitive Advantages:
- Strong brand recognition and reputation for quality
- Innovative technology and product portfolio
- Global reach and distribution network
Competitive Disadvantages:
- Intense competition in the industry
- Dependence on key markets and customers
- Potential for technological disruption
Potential Challenges & Opportunities:
Challenges:
- Supply chain disruptions
- Technological advancements by competitors
- Economic downturns
Opportunities:
- Expanding into new markets and applications
- Developing new analytical techniques
- Leveraging digitalization and data analytics
Recent Acquisitions:
- Chromatography.com (2021): This acquisition expanded Waters' reach in the online marketplace for chromatography supplies.
- Wyatt Technology (2021): This acquisition strengthened Waters' position in light scattering technologies for protein characterization.
- Evolva (2022): This acquisition broadened Waters' portfolio of cell culture and fermentation technologies for biopharmaceutical manufacturing.
AI-Based Fundamental Rating:
Rating: 8/10
Justification:
Waters Corporation scores highly on several fundamental metrics, including financial health, market position, and growth potential. Its strong brand recognition, innovative technology, and consistent financial performance make it an attractive investment opportunity. However, the company faces challenges from intense competition and potential technological disruptions.
Disclaimer:
The information provided in this overview is based on publicly available data and should not be considered investment advice. Investors should conduct their own due diligence before making any investment decisions.
Sources:
- Waters Corporation Investor Relations
- SEC filings
- Industry reports
- Analyst coverage
Please note that this information is current as of October 26, 2023, and may not reflect subsequent developments.
About Waters Corporation
Exchange NYSE | Headquaters Milford, MA, United States | ||
IPO Launch date 1995-11-16 | President, CEO & Director Dr. Udit Batra Ph.D. | ||
Sector Healthcare | Industry Diagnostics & Research | Full time employees 7600 | Website https://www.waters.com |
Full time employees 7600 | Website https://www.waters.com |
Waters Corporation provides analytical workflow solutions in Asia, the Americas, and Europe. It operates through two segments: Waters and TA. The company designs, manufactures, sells, and services high and ultra-performance liquid chromatography, as well as mass spectrometry (MS) technology systems and support products, including chromatography columns, other consumable products, and post-warranty service plans. It also designs, manufactures, sells, and services thermal analysis, rheometry, and calorimetry instruments; and develops and supplies software-based products that interface with its instruments, as well as other manufacturers' instruments. In addition, the company offers MS technology instruments are used in drug discovery and development comprising clinical trial testing, the analysis of proteins in disease processes, nutritional safety analysis, and environmental testing. Further, the company provides thermal analysis, rheometry, and calorimetry instruments for use in predicting the suitability and stability of fine chemicals, pharmaceuticals, water, polymers, metals, and viscous liquids for various industrial, consumer good, and healthcare products, as well as for life science research. Its products are used by clinical, pharmaceutical, biochemical, industrial, nutritional safety, environmental, academic, and governmental customers working in research and development, quality assurance, and other laboratory applications. The company was founded in 1958 and is headquartered in Milford, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.